All In Biotech

Drug Trial Radar · NCT00650039

Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg QD And Valdecoxib 20 Mg BID Compared To Placebo Over Multiple Days For Management Of Acute Postsurgical Pain In Patients Undergoing Anterior Cruciate Ligament Reconstruction

Last checked: Nov 20, 2026Latest source record: Jun 4, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 488 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

488

Actual

Start

Mar 2004

Primary completion

Not stated

Study completion Feb 2005

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 1, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to evaluate the analgesic efficacy of valdecoxib 20 mg daily and valdecoxib 20 mg twice daily compared with placebo in outpatients with moderate-severe pain after arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. Secondary objectives were to compare each valdecoxib dose with placebo on additional measures of pain intensity, health outcomes, the use of rescue medication, and the occurrence of opioid-related symptoms, and to evaluate their safety.

Conditions

  • Pain

Interventions

  • placeboDrug

    valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.

  • valdecoxibDrug

    valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.

  • valdecoxibDrug

    valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summed Pain Intensity (categorical) through 24 hours (SPI 24)Time frame: Day 2 and Day 3
  2. Patient's Global Evaluation of Study Medication (PGESM)Time frame: Day 2 and Day 3

Locations

81 sites in 2 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Northport, Alabama

  • Pfizer Investigational Site

    Glendale, Arizona

  • Pfizer Investigational Site

    Pheonix, Arizona

  • Pfizer Investigational Site

    Pheonix, Arizona

  • Pfizer Investigational Site

    Pheonix, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Tempe, Arizona

  • Pfizer Investigational Site

    Glendale, California

  • Pfizer Investigational Site

    Laguna Hills, California

  • Pfizer Investigational Site

    Laguna Woods, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Avon, Connecticut

  • Pfizer Investigational Site

    Cromwell, Connecticut

  • Pfizer Investigational Site

    Enfield, Connecticut

  • Pfizer Investigational Site

    Farmington, Connecticut

  • Pfizer Investigational Site

    Farmington, Connecticut

  • Pfizer Investigational Site

    Glastonbury, Connecticut

  • Pfizer Investigational Site

    Hartford, Connecticut

  • Pfizer Investigational Site

    Hartford, Connecticut

  • Pfizer Investigational Site

    Rocky Hill, Connecticut

  • Pfizer Investigational Site

    Windsor, Connecticut

  • Pfizer Investigational Site

    Hollywood, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Plantation, Florida

  • Pfizer Investigational Site

    Saint Augustine, Florida

  • Pfizer Investigational Site

    St. Petersburg, Florida

  • Pfizer Investigational Site

    Weston, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Morrow, Georgia

  • Pfizer Investigational Site

    Stockbridge, Georgia

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Oak Park, Illinois

  • Pfizer Investigational Site

    Cedar Rapids, Iowa

  • Pfizer Investigational Site

    Lexington, Kentucky

  • Pfizer Investigational Site

    Lexington, Kentucky

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.